TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Applying Mobile Persuasive Technologies to Increase Physical Activity in Women
Brief Summary: The primary purpose of this study is to assess the efficacy of the mobile phone-based physical activity intervention on increasing physical activity compared to the control group.


Options:
A: Inclusion Criteria:

* Sedentary lifestyle at work and/or during leisure time
* Intend to be physically active
* Female, age \>25 to 69
* Access to a home telephone or a mobile phone
* Speak and read English

Exclusion Criteria:

* Known medical conditions or other physical problems that need special attention in an exercise program
* Plan a trip abroad during the first 4 months of the study period.
* Pregnant/Delivered a baby during the last 6 months
* Known severe hearing or speech problem
* Body Mass Index (BMI) \> 43.0 kg/m2
* Currently participate in lifestyle modification programs or research studies that may potentially confound the results of the study
* History of bariatric surgery or future plans for bariatric surgery in the next 12 months
B: Inclusion Criteria:

* Residents of the 20 most deprived neighbourhoods in the city of Sheffield
* Aged 40 to 64 years
* Not achieving the current recommended activity level (30 mins of moderate activity on at least 5 days) assessed using the SPAQ (Lowther, 1999) and wishing to have support to become more active

Exclusion Criteria:

* Have increased their physical activity level by at least 30 mins of moderate or vigorous activity per week (assessed using the SPAQ) since initial assessment of activity level
* Capacity to give written informed consent to trial participation
C: Patients that will be included into the study if they have either / or

* Diagnosed with Pre-Diabetes (IGT or IFG)
* Aged 40 - 75 if English speaking European or 25 - 75 if South Asian
* Able to attend group education sessions

Exclusion Criteria:

Patients will be excluded from the study if they are:

* Unable to give consent
* Unable to attend group education sessions
* Diagnosis of diabetes at screening or during the study
* Require an interpreter for language other than South Asian
D: Inclusion Criteria:

* self-identified Korean American ethnicity
* age 18 years or older
* daily smoker (i.e., smoked at least one cigarette per day during the previous seven days)
* current U.S. resident
* valid email address
* regular internet access.

Exclusion Criteria: None

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Applying Mobile Persuasive Technologies to Increase Physical Activity in Women
Brief Summary: The primary purpose of this study is to assess the efficacy of the mobile phone-based physical activity intervention on increasing physical activity compared to the control group.


Options:
A: Inclusion Criteria:

* Residents of the 20 most deprived neighbourhoods in the city of Sheffield
* Aged 40 to 64 years
* Not achieving the current recommended activity level (30 mins of moderate activity on at least 5 days) assessed using the SPAQ (Lowther, 1999) and wishing to have support to become more active

Exclusion Criteria:

* Have increased their physical activity level by at least 30 mins of moderate or vigorous activity per week (assessed using the SPAQ) since initial assessment of activity level
* Capacity to give written informed consent to trial participation
B: Inclusion Criteria:

* Sedentary, defined as exercising less than 90 minutes per week
* Lack of access to the Internet
* Lack of access to receiving mail

Exclusion Criteria:

* Coronary heart disease (history of myocardial infarction or symptoms of angina)
* Diabetes
* Stroke
* Osteoarthritis
* Osteoporosis
* Orthopedic problems which would limit treadmill testing
* Other medical or psychological problems that could make adherence with the study protocol difficult or dangerous
* Consumption of three or more alcoholics drinks per day
* Current or planned pregnancy
* Planning to move from the area within the next year
* Current suicidal ideation or psychosis
* Current clinical depression
* Recent hospitalization due to a psychiatric disorder
* Taking medication that may impair physical activity tolerance or performance (e.g., beta blockers).
C: Inclusion Criteria:

* mother of infant aged 2-12 months
* sedentary
* healthy, able to do moderate intensity physical activity
* BMI = 18.5-40
* not planning to become pregnant in next year
* woman aged 18-45
* able speak and read English

Exclusion Criteria:

* pregnant
* planning to leave Oahu, Hawaii in the next year (permanently move away)
* a diagnosis of cancer, coronary heart disease (including atrial fibrillation), insulin-dependent diabetes mellitus (IDDM), and other atherosclerotic cardiovascular diseases (e.g., stroke),
D: Inclusion Criteria:

* Sedentary lifestyle at work and/or during leisure time
* Intend to be physically active
* Female, age \>25 to 69
* Access to a home telephone or a mobile phone
* Speak and read English

Exclusion Criteria:

* Known medical conditions or other physical problems that need special attention in an exercise program
* Plan a trip abroad during the first 4 months of the study period.
* Pregnant/Delivered a baby during the last 6 months
* Known severe hearing or speech problem
* Body Mass Index (BMI) \> 43.0 kg/m2
* Currently participate in lifestyle modification programs or research studies that may potentially confound the results of the study
* History of bariatric surgery or future plans for bariatric surgery in the next 12 months

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis
Brief Summary: The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).


Options:
A: Inclusion Criteria:

* Aged 18 to 80 years old, inclusive, on Day 1.
* Diagnosis of sporadic or familial ALS.
* Onset of first ALS symptoms within 24 months prior to Day 1.
* World Federation of Neurology El Escorial criteria are met for a possible, laboratory-supported probable, probable, or definite ALS diagnosis.
* Upright slow vital capacity (SVC) of 65% or more at screening.
* Patients taking or not taking Riluzole are eligible for this study: if a patient has never taken Riluzole, he or she is eligible; if a patient is currently taking Riluzole, he or she must have been on a stable dose for at least 60 days; if a patient has discontinued Riluzole, he or she must have stopped taking it for at least 30 days.
* Must be able to swallow tablets at the time of study entry.

Exclusion Criteria:

* Other medically significant illness.
* Clinically significant abnormal laboratory values.
* Pregnant women or women breastfeeding.
* Prior exposure to dexpramipexole.
* Currently taking pramipexole or other dopamine agonists.

Other protocol-defined inclusion/exclusion criteria may apply.
B: Inclusion Criteria:

* Cigarette smoker (daily smoker when smoking in usual way during the month before hospital admission)
* Counseled by hospital smoking counselor during hospital stay
* Plans to stop smoking tobacco products after hospital discharge
* Appropriate for use of smoking cessation medication after discharge

Exclusion Criteria:

* Expected hospital length of stay \<24 hours
* Not expected to be discharged to home
* No access to a telephone
* Unable to communicate by telephone
* Severe psychiatric or neurologic disease precluding ability to be counseled
* Pregnant, nursing, or planning to become pregnant in next 3 months
* Active substance abuse other than tobacco
* Unable to speak English
C: Inclusion Criteria:

* age 18 years or older
* hospitalized for heart failure within the past 30 days
* access to telephone line

Exclusion Criteria:

* not expected to survive 6 months due to irreversible, life-threatening condition
* has or scheduled for cardiac transplant or LVAD
* scheduled for CABG or PCI within 90 days
* severe valvular disease
* Folstein MMSE score less than 20
* resident of a nursing home
* currently a prisoner
* does not speak English or Spanish
D: Inclusion Criteria:

* TRICARE Prime non-active-duty beneficiaries
* Body Mass Index of 25 to 50
* Living in 4 midwestern states (TRICARE region)

Exclusion Criteria:

* Not able to engage in physical activity
* Pregnant
* Body mass index greater than 50
* Body mass index less than 25
* Human immunodeficiency virus infected
* current cancer

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Education Interventions Model for Rational Drug Use
Brief Summary: The purpose of this study is to develop, implement and evaluate an economically viable and efficient interventions education model for rational drug use, adaptable to different pathological situations and should be implemented into Brazil Heath Care System.


Options:
A: Inclusion Criteria:

* pharmacies: resident in the south of the Netherlands
* patients: with antiplatelet therapy and without lipid-lowering medication

Exclusion Criteria:for patients:

* terminal disease
* severe mental disorder
B: Inclusion Criteria:

* Subject with asthma diagnosed according to criteria of the Global Strategy for Asthma Management and Prevention;
* Subject is a male or female with 18 to 73 years-old;
* Subject who has access to medications supplied by the the Brazil Heath Care System;
* Subject unable to perform the procedures or conditions such as pregnancy that may affect the results of the study;
* Literate subject without Cognitive Disorders, Alzheimer's, Dementia, that can limit the ability to participate in this study;
* Subject who have availability to attend the monthly meetings;
* Subject provides written informed consent and attend the first evaluation.

Exclusion Criteria:

* Subject who cannot be classified in the inclusion criteria.
C: Inclusion Criteria:

* Must be 18 years old or above
* Capable of understanding and willing to provide voluntary informed consent before any protocol specific procedures are performed
* Capable of understanding and complying with the requirements of the protocol, and demonstrating a willingness to attend for all required visits.
* Able and willing to take inhaled medication.
* Have a valid prescription for use of a Seretide diskus inhaler or already using a Seretide diskus inhaler.
* Have a history of regular attendance in the pharmacy in which they are recruited which will be demonstrated by the subject having collected three prescriptions for any medication in that pharmacy in the six months preceeding their recruitment to the study.

Exclusion Criteria:

* Patient expressly reports that their physician has indicated that they will not be continuing to receive Seretide over the next 6 months
D: Inclusion Criteria:is African American and 18 years old or older; has active prescription for BP drug; obtains all BP drugs at the study pharmacy; is able to read and fill out short questionnaires; is able to come to pharmacy for 6 monthly pharmacy visits if needed; has screening BP between 140/90 mm Hg and 210/115 mm Hg.

Exclusion Criteria: history of organ transplant or kidney dialysis, symptoms of advanced congestive heart failure, memory impairment that interferes with daily functioning,terminal illness,pregnancy, alcohol or substance abuse problem,physician recommendation of exclusion for other condition that may require special care or limit participation in the study.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Novel Sustainable Complementary Feeding Product for Infants and Young Children in the Democratic Republic of Congo: Caterpillar Cereal
Brief Summary: Two in every three infants in rural areas of the Democratic Republic of Congo (DRC) suffer from stunting of linear growth by 12 months of age. Stunting presumably results from breast milk supplementation after 6 months of age with complementary foods (CF) that provide inadequate protein and micro-nutrients. Although supplementation with selected micro-nutrients may avoid certain deficiency states, CF with animal source foods may be necessary to avoid stunting. Meat is not readily available in many Central African countries. However caterpillars, which are locally available and abundant, are a common staple in adult diets and may be a suitable substitute for animal source proteins in CF. The investigators developed a cereal made from dried caterpillars that has a nutrient content that appears to be ideal for CF and demonstrated maternal and infant acceptability. This study will investigate the efficacy in prevention of stunting of growth resulting from inadequate complementary foods.

A sub-study will evaluate the biologic effects of the caterpillar cereal to determine whether caterpillar cereal prevents iron deficiency anemia, reduces the incidence of neurodevelopmental impairment or infectious diseases.


Options:
A: Inclusion Criteria:

* child is healthy and between the age of 6 months to 9 months

Exclusion Criteria:

* age of child
* any reactions to eating to eggs, a rash, hives, difficulty breathing
B: Inclusion Criteria:

* Infants born in study communities who will reach 6 months of age during the six month period after initiation of the study

Exclusion Criteria:

* Infants likely to receive free or subsidized complementary foods (or infant formula)
* Families likely to relocate during the study period
* Infants with known congenital anomaly
* Infants of multiple birth
* Infants with neurological deficit apparent at the time of enrollment
C: Inclusion Criteria:

* a term healthy newborn infant (birth weight \> 2500 g, gestational age \> 37 weeks);
* inclusion during the first two months of life.
* German speaking mother;
* the intention of the mother to breast-feed the child and to feed study menus 5 to 7 times per week beginning in the fifth to seventh month of life.

Exclusion Criteria:

* preterm infants
D: Inclusion Criteria:

* 1-5 months of age
* Formula fed
* On breast milk less than 1 month
* Healthy
* Term Birth (36-42 weeks)
* Appropriate for gestational age

Exclusion Criteria:

* Congenital anomalies that impact feeding, growth, or development
* Low birth weight
* Not able to consume milk-based formula
* Known chronic diseases or allergies affecting protein consumption/digestion

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Intraoperative Lung Protective Ventilation in Abdominal Surgery: A Randomized Controlled Study
Brief Summary: The purpose of this study is to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery.


Options:
A: Inclusion Criteria:

* Planned intrabdominal surgery
* Expected duration ≥ 2 hours
* Age ≥ 40 yr (and \<90 yr)
* Risk of postoperative pulmonary complications (Arozullah score ≥2)

Exclusion Criteria:

* Noninvasive ventilation in the last 30 days
* Recent history of pneumonia, ALI/ARDS (in the last 30 days)
* History of pulmonary resection
* History of neuromuscular disease
* Patient refusal
B: Inclusion Criteria:

* Colon resection expected to last \>2 and \<6 hours

Exclusion Criteria:

* Bowel obstruction
* Fever
C: Inclusion Criteria:

* Age not less than 18
* Risk of postoperative pulmonary complication moderate-high defined by a score ≥ 26 on the risk scale ARISCAT (based on the analysis of seven factors, where a score between 26 and 44 points defines a moderate risk, and a score\> 44 points define a high risk, included in the Information Booklet Investigator).
* Planned abdominal surgery\> 2 hours.
* Signed informed consent for participation in the study.

Exclusion Criteria:

* Age less than 18 years.
* Pregnant or breast-feeding.
* Patients with BMI \>35.
* Syndrome of moderate or severe respiratory distress: PaO2/FiO2 \< 200 mmHg.
* Heart failure: NYHA IV.
* Hemodynamic failure: CI \<2.5 L/min/m2 and / or requirements before surgery ionotropic support.
* Diagnosis or suspicion of intracranial hypertension (intracranial pressure\> 15 mmHg).
* Mechanical ventilation in the last 15 days.
* Presence of pneumothorax. Presence of giant bullae on chest radiography or computed tomography (CT).
* Patient with preoperatively CPAP.
* Participation in another experimental protocol at the time of intervention selection.
D: Inclusion Criteria:

* Age: 18-65 years
* Chest X-ray: no infiltrates
* Duration of mechanical ventilation from the admission to ICU to the clinical diagnosis of brain death \< 5 days
* No history of Smoking (1 pack/day for 20 years; 1/2 pack/day for 40 years; 2 packs/day for 10 years)
* No history of Asthma
* No history of COPD
* No history of Trauma
* No history of Thoracic surgery

Exclusion Criteria:

* Evidence of aspiration (chest X-ray or bronchoscopy) or sepsis
* Purulent secretions (tracheal suction or bronchoscopy)
* Sputum Gram stain with bacteria, fungus, significant number of WBC

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial
Brief Summary: There will be no significant differences in the efficacy and tolerability between the test and reference formulations of atorvastatin 20 mg in these Korean adults with primary hypercholesterolemia.


Options:
A: Inclusion Criteria:

* the patients aged 20 to 79 years with primary hypercholesterolemia that was not sufficiently responsive to therapeutic lifestyle changes and had LDL-C level over 100 mg/dL in high risk group.
* Inclusion criteria was in accordance with drug treatment guidelines; coronary artery disease or equivalent group with LDL-C ≥100 mg/dl; patients with two or more risk factors and LDL-C≥130 mg/dl; patients with 0 or 1 risk factor and LDL-C \>160 mg/dl after therapeutic lifestyle changes

Exclusion Criteria:

* therapy with any other investigational drug within 30 days of randomization,
* history of hypersensitivity to HMG-CoA reductase inhibitors,
* uncontrolled hypertension,
* poorly controlled diabetes (glycosylated hemoglobin \[HbA1c\] \>9%),
* unstable angina or presented with new-onset myocardial infarction (within 6 months),
* creatinine \>2.5 mg/dl,
* alanine aminotransferase (ALT) \>2 x upper limit of normal (ULN), aspartate aminotransferase(AST) \>2 x ULN, or creatine kinase (CK) \>2 x ULN,
* history of malignancy or psychosis;
* chronic liver disease,
* drug or alcohol abuse, pregnancy, breastfeeding, failure to practice adequate contraception, cyclical hormonal contraceptives or intermittent use of hormone replacement therapies.
B: Inclusion Criteria:

* clinically defined lacunar syndrome 3 months before inclusion
* small deep infarct on diffusion MRI (Diffusion Weighted Imaging)
* no atherothrombotic, cardio-embolic, or other rarer cause.

Exclusion Criteria:

* patients with past coronary event
* contra-indication for assessment of vasomotor reactivity
* patients being on statin therapy at the time of brain infarction
* contra-indication for statin therapy
* patient still under statin therapy
C: Inclusion Criteria:

1. Type 2 DM
2. Hypercholesterolemia (baseline screening LDL-C \> 100 mg/dL)
3. In case of medication, stable doses of oral hypoglycemic agents for at least three months
4. HbA1c \<8.5%
5. Age: 20-80

Exclusion Criteria:

1. Chronic renal failure: creatinine \> 3.0 mg/dL
2. Serious liver disease (\> x3 LFT UNL)
3. Congestive heart failure
4. Stroke or MI/coronary intervention during the preceding 3 months.
5. CK \> x 2.5 UNL
6. Unstable hypo/hyperthyroidism
7. Pregnant/lactating woman, or woman intending to become pregnant
8. Subject with any clinically significant condition or situation, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study.
D: Inclusion Criteria:

* hypercholesterolemia

Exclusion Criteria:

* chronic renal disease

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Primary Prevention of Allergic Disease in Early Child by Lactobacillus Reuteri
Brief Summary: An altered microbial exposure may be partly responsible for the increase of allergic diseases in populations with a western lifestyle. Activation of the immune system by microbes early in life is probably required for an accurate maturation of the immune system. Probiotics, live bacteria which are considered to confer health when ingested, have been suggested to prevent eczema and sensitisation infants.

The aim of this study is to assess the effect of oral supplementation with the probiotic bacterium Lactobacillus reuteri in infancy on the development of allergic disease and sensitisation during the first 2 years of life and to examine mechanisms possibly underlying eventual effects on allergic manifestations.

A follow up was performed at 7 years of age.


Options:
A: Inclusion Criteria:

* Pregnant women with history of previous or present allergic disease in at least one member of the immediate family (parents or siblings).
* Expected compliance.
* Written informed consent obtained from parents.

Exclusion Criteria:

* Insufficient compliance, i.e. a consumption of the study product below half of the expected.
B: Inclusion Criteria:

* Pregnant women with atopic disease, which was determined with atopic history, elevated total IgE \> 100 kU/l and positive specific IgE

Exclusion Criteria:

* Multiple pregnancy
C: Inclusion Criteria:

1. Age between 1 year old and 18 years old,
2. AD cases fulfill the diagnostic criteria by Hannifin and Rajka.
3. Atopy as shown by at least one positive skin test (weal size ≧ 3mm) or one positive MAST (RAST) (IgE ≧ 0.7 kU/L) test to any common food or environmental allergens.

Exclusion Criteria:

1. Systematic corticosteroid, immunosuppressive therapy, or antimycotics treatment during the 4 weeks, antihistamines, and singulair during the 7 days before enrollment
2. Probiotic preparations used within 2 weeks before entering the study
3. Use of antibiotics now or other oral medications that will interfere the results
4. If they had immune deficiency disease or other major medical problems
5. If they had participated in another clinical study during the past month.
6. Subjects are undergoing desensitization therapy within 3 months prior to the screening period.
7. Subjects have participated investigational drug trial within 4 weeks before entering this study.
8. Subjects are pregnant, lactating or planning to become pregnant.
9. Subjects with any other serious diseases considered by the investigator that could interfere with the performance of SCORAD score result.
10. Subjects who is lack of physical integrity of gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication.
D: Inclusion Criteria:

* clinical diagnosis of atopic dermatitis
* age 4 we - 18 mo

Exclusion Criteria:

* skin infection or severe infection at the time of enrollment

Answer: A